MetaCan

MetaCan is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs targeting cancer metabolism. Based in Shanghai, China, the company utilizes its deep expertise in metabolic pathways to develop small molecule inhibitors that disrupt the energy supply and microenvironment of tumor cells. Its lead program, MC001, is a potent and selective MCT1 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. MetaCan's broader pipeline includes programs targeting MCT4 and glutaminase, aiming to address unmet medical needs in oncology through metabolic reprogramming. The company is backed by prominent life science investors and maintains a strong focus on precision oncology.